Sonoma Pharma Seeks Stockholder Votes for Annual Meeting
Ticker: SNOA · Form: DEFA14A · Filed: Jul 24, 2024 · CIK: 1367083
Sentiment: neutral
Topics: proxy-solicitation, annual-meeting, corporate-governance
TL;DR
Sonoma Pharma needs your vote for the Aug 14th meeting - don't miss the quorum!
AI Summary
Sonoma Pharmaceuticals, Inc. is soliciting proxies for its annual meeting of stockholders scheduled for August 14, 2024. The company is urging stockholders who have not yet voted to do so promptly to ensure a quorum is present. The record date for determining stockholders entitled to vote was June 21, 2024.
Why It Matters
This filing is important because it directly involves shareholder participation in corporate governance, ensuring that the company can conduct its official business at the annual meeting.
Risk Assessment
Risk Level: low — This is a routine proxy solicitation for an annual meeting and does not contain significant new financial or strategic information.
Key Players & Entities
- Sonoma Pharmaceuticals, Inc. (company) — Filer of the DEFA14A
- August 14, 2024 (date) — Date of the Annual Meeting
- June 21, 2024 (date) — Record date for determining stockholders
FAQ
What is the purpose of this DEFA14A filing?
The purpose of this DEFA14A filing is to solicit proxies from stockholders of Sonoma Pharmaceuticals, Inc. for their annual meeting.
When is the annual meeting of Sonoma Pharmaceuticals, Inc. scheduled to be held?
The annual meeting of stockholders of Sonoma Pharmaceuticals, Inc. is scheduled to be held on August 14, 2024.
What is the record date for determining stockholders entitled to vote at the annual meeting?
The record date for determining stockholders entitled to vote at the annual meeting was June 21, 2024.
Why is the company sending out this proxy solicitation?
The company is sending out this proxy solicitation because it has not yet received votes from all shareholders and needs to ensure a quorum is present for the annual meeting.
What was Sonoma Pharmaceuticals, Inc. formerly known as?
Sonoma Pharmaceuticals, Inc. was formerly known as Oculus Innovative Sciences, Inc., with a name change date of June 22, 2006.
Filing Stats: 311 words · 1 min read · ~1 pages · Grade level 7.5 · Accepted 2024-07-24 07:30:03
Filing Documents
- sonoma_defa14a.htm (DEFA14A) — 6KB
- image_001.jpg (GRAPHIC) — 4KB
- image_002.jpg (GRAPHIC) — 3KB
- 0001683168-24-005018.txt ( ) — 17KB
From the Filing
14A 5445 Conestoga Court, Suite 150 Boulder, Colorado 80301 (800) 759-9305 YOUR VOTE IS IMPORTANT PLEASE VOTE YOUR PROXY TODAY July 24, 2024 Dear Fellow Stockholder: We are reaching out to you regarding the proxy materials that you recently received in connection to the annual meeting of stockholders of Sonoma Pharmaceuticals, Inc. (the “Company” or “Sonoma”) scheduled to be held on August 14, 2024 (the “Annual Meeting”). Your vote is extremely important, regardless of the number of shares you own. Whether or not you expect to attend the Annual Meeting, please vote your shares as promptly as possible so that your shares may be represented and voted at the Annual Meeting. This letter is being sent to you because you held shares of Sonoma on the record date, June 21, 2024, and we have not yet received your vote. In order to hold the annual meeting, we need to have a quorum present. Your vote is extremely important, no matter how many shares you hold or how you choose to vote. PLEASE VOTE YOUR SHARES TODAY. For the reasons set forth in the proxy statement dated July 1, 2024, your Board of Directors unanimously recommends you vote “FOR” the election of two director nominees and “FOR” proposals 2, 3, 4, 5, 6, 7 and 8. Please vote via the internet or sign, date and return the enclosed voting instruction form as soon as possible. We have retained D.F. King & Co., Inc. (“D.F. King”) to solicit proxies for us. We have agreed to reimburse D.F. King for reasonable expenses. If you need assistance in voting your shares, please feel free to call D.F. King at (877) 283-0320. On behalf of your Board of Directors, thank you for your ongoing support of, and continued interest in, our Company. Sincerely, Bruce Thornton Executive Vice President, Chief Operating Officer and Corporate Secretary Boulder, Colorado